Details of the Drug

General Information of Drug (ID: DMA2Z4F)

Drug Name

Minoxidil

Synonyms

Alopexil; Alostil; Loniten; Lonolox; Minodyl; Minossidile; Minoxidilum; Minoxigaine; Minoximen; Neoxidil; Normoxidil; Pierminox; Prexidil; Regaine; RiUP; Rogaine; Theroxidil; Tricoxidil; Trocoxidil; MINOXIDIL EXTRA STRENGTH FOR MEN; Men s Rogaine Foam; Mens Rogaine Foam; Minossidile [Italian]; Minoxidil Pfizer Brand; PfizerBrand of Minoxidil; Rogaine Extra Strength for Men; Rogaine for Men; Rogaine for Women; M 4145; M1389; U 10858; Apo-Gain; Gen-Minoxidil; Loniten (TN); MINOXIDIL (FOR MEN); MINOXIDIL (FOR WOMEN); MINOXIDIL EXTRA STRENGTH (FOR MEN); Men's Rogaine; Minoxidilum [INN-Latin]; ROGAINE (FOR MEN); ROGAINE (FOR WOMEN); ROGAINE EXTRA STRENGTH (FOR MEN); Regaine (TN); Riup (TN); Rogaine (TN); TM-160; U-10858; Minoxidil (USP/INN); Minoxidil [USAN:BAN:INN]; U-10,858; Rogaine, Regaine, Avacor and Mintop, Minoxidil; Pyrimidine, 2,4-diamino-6-piperidino-, 3-oxide; 2,3-Dihydro-3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine; 2,4-Diamino-6-piperidinilpirimidina-3-ossido; 2,4-Diamino-6-piperidinilpirimidina-3-ossido [Italian]; 2,4-Diamino-6-piperidino-pyrimidine-3-oxide; 2,4-Diamino-6-piperidinopyrimidine 3-N-oxide; 2,4-Diamino-6-piperidinopyrimidine 3-oxide; 2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide; 2,6-Diamino-4-piperidinopyrimidin-1-oxid; 3-hydroxy-2-imino-6-(1-piperidyl)pyrimidin-4-amine; 3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine; 6-(1-Piperidinyl)-2,4-pyrimidinediamine 3-oxide; 6-(piperidin-1-yl)pyrimidine-2,4-diamine 3-oxide; 6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine; 6-Piperidino-2,4-diaminopyrimidine 3-oxide; 6-[1-Piperidinyl]pyrimidine-2,4-diamine 3 oxide

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Approved	[1], [2]

Therapeutic Class

Antihypertensive Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

209.25

Topological Polar Surface Area (xlogp)

1.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: 95% of drug becomes completely available to its intended biological destination(s) [4]
Clearance: The drug present in the plasma can be removed from the body at the rate of 11.5 mL/min/kg [5]
Elimination: 10% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 4.2 hours [5]
Metabolism: The drug is metabolized via the conjugation with glucuronic acid at the N-oxide position in the pyrimidine ring [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 6.8271 micromolar/kg/day [7]
Unbound Fraction: The unbound fraction of drug in plasma is 1% [5]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.9 L/kg [5]
Water Solubility: The ability of drug to dissolve in water is measured as 2.2 mg/mL [3]

Chemical Identifiers

Formula: C9H15N5O
IUPAC Name: 3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine
Canonical SMILES: C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O
InChI: InChI=1S/C9H15N5O/c10-7-6-8(12-9(11)14(7)15)13-4-2-1-3-5-13/h6,11,15H,1-5,10H2
InChIKey: ZIMGGGWCDYVHOY-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4201
ChEBI ID: CHEBI:6942
CAS Number: 38304-91-5
DrugBank ID: DB00350
TTD ID: D0Y2CJ
INTEDE ID: DR1095
ACDINA ID: D00438

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Potassium channel unspecific (KC)	TT1VOHK	NOUNIPROTAC	Modulator	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[9]
Sulfotransferase 1A1 (SULT1A1)	DEYWLRK	ST1A1_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Minoxidil (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Promazine	DMZAL7W	Moderate	Additive hypotensive effects by the combination of Minoxidil and Promazine.	Appearance/behaviour symptom [MB23]	[35]
Linezolid	DMGFPU2	Moderate	Additive hypotensive effects by the combination of Minoxidil and Linezolid.	Bacterial infection [1A00-1C4Z]	[36]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Minoxidil and Cariprazine.	Bipolar disorder [6A60]	[35]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Minoxidil and Olopatadine.	Conjunctiva disorder [9A60]	[37]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Minoxidil and Selegiline.	Depression [6A70-6A7Z]	[36]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Minoxidil and Isocarboxazid.	Depression [6A70-6A7Z]	[36]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Minoxidil and Tranylcypromine.	Depression [6A70-6A7Z]	[36]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Minoxidil and OPC-34712.	Depression [6A70-6A7Z]	[35]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Minoxidil and Phenelzine.	Depression [6A70-6A7Z]	[36]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Minoxidil and Procarbazine.	Hodgkin lymphoma [2B30]	[36]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Minoxidil and Propiomazine.	Insomnia [7A00-7A0Z]	[35]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Minoxidil and ITI-007.	Insomnia [7A00-7A0Z]	[35]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Minoxidil and Ozanimod.	Multiple sclerosis [8A40]	[36]
Prochlorperazine	DM53SRA	Moderate	Additive hypotensive effects by the combination of Minoxidil and Prochlorperazine.	Nausea/vomiting [MD90]	[35]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Minoxidil and Promethazine.	Nausea/vomiting [MD90]	[35]
Thiethylperazine	DMU3IET	Moderate	Additive hypotensive effects by the combination of Minoxidil and Thiethylperazine.	Nausea/vomiting [MD90]	[35]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Minoxidil and Safinamide.	Parkinsonism [8A00]	[36]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Minoxidil and Rasagiline.	Parkinsonism [8A00]	[36]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Minoxidil and Levomepromazine.	Psychotic disorder [6A20-6A25]	[35]
Fluphenazine	DMIT8LX	Moderate	Additive hypotensive effects by the combination of Minoxidil and Fluphenazine.	Psychotic disorder [6A20-6A25]	[35]
Triflupromazine	DMKFQJP	Moderate	Additive hypotensive effects by the combination of Minoxidil and Triflupromazine.	Psychotic disorder [6A20-6A25]	[35]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Minoxidil and Quetiapine.	Schizophrenia [6A20]	[35]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Minoxidil and Mesoridazine.	Schizophrenia [6A20]	[35]
Thioridazine	DM35M8J	Moderate	Additive hypotensive effects by the combination of Minoxidil and Thioridazine.	Schizophrenia [6A20]	[35]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Minoxidil and Aripiprazole.	Schizophrenia [6A20]	[35]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Minoxidil and Iloperidone.	Schizophrenia [6A20]	[35]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Minoxidil and Paliperidone.	Schizophrenia [6A20]	[35]
Loxapine	DM8AI9U	Moderate	Additive hypotensive effects by the combination of Minoxidil and Loxapine.	Schizophrenia [6A20]	[35]
Haloperidol	DM96SE0	Moderate	Additive hypotensive effects by the combination of Minoxidil and Haloperidol.	Schizophrenia [6A20]	[35]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Minoxidil and Perphenazine.	Schizophrenia [6A20]	[35]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Minoxidil and Molindone.	Schizophrenia [6A20]	[35]
Chlorpromazine	DMBGZI3	Moderate	Additive hypotensive effects by the combination of Minoxidil and Chlorpromazine.	Schizophrenia [6A20]	[35]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Minoxidil and Thiothixene.	Schizophrenia [6A20]	[35]
Clozapine	DMFC71L	Moderate	Additive hypotensive effects by the combination of Minoxidil and Clozapine.	Schizophrenia [6A20]	[35]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Minoxidil and Trifluoperazine.	Schizophrenia [6A20]	[35]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Minoxidil and Risperidone.	Schizophrenia [6A20]	[35]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Minoxidil and Amisulpride.	Schizophrenia [6A20]	[35]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Minoxidil and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[35]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Minoxidil and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[38]
-----------


⏷ Show the Full List of 39 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Docusate sodium	E00563	23673837	Surfactant
Sodium benzoate	E00432	517055	Antimicrobial preservative; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Minoxidil 10 mg tablet	10 mg	Oral Tablet	Oral
Minoxidil 2.5 mg tablet	2.5 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4254).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 071344.
3	BDDCS applied to over 900 drugs
4	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9	Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos. 2004 Apr;32(4):413-23.
10	Sulfation of minoxidil by multiple human cytosolic sulfotransferases. Chem Biol Interact. 1998 Feb 20;109(1-3):53-67.
11	Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
12	Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
13	Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
14	UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
15	Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
16	Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
17	Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
18	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
19	Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
20	Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
21	Progestagenic effects of tibolone are target gene-specific in human endometrial cells. J Soc Gynecol Investig. 2006 Sep;13(6):459-65.
22	Tamoxifen-induced adduct formation and cell stress in human endometrial glands. Drug Metab Dispos. 2010 Jan;38(1):200-7.
23	Proposed role of the sulfotransferase/sulfatase pathway in modulating yolk steroid effects. Integr Comp Biol. 2008 Sep;48(3):419-27.
24	Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2008 Mar;82(3):155-65.
25	Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
26	Natural products isolated from Mexican medicinal plants: novel inhibitors of sulfotransferases, SULT1A1 and SULT2A1. Phytomedicine. 2001 Nov;8(6):481-8.
27	Kinetic analysis of bile acid sulfation by stably expressed human sulfotransferase 2A1 (SULT2A1). Xenobiotica. 2010 Mar;40(3):184-94.
28	Characterization of human liver thermostable phenol sulfotransferase (SULT1A1) allozymes with 3,3',5-triiodothyronine as the substrate. J Endocrinol. 2001 Dec;171(3):525-32.
29	Crystal structure of human sulfotransferase SULT1A3 in complex with dopamine and 3'-phosphoadenosine 5'-phosphate. Biochem Biophys Res Commun. 2005 Sep 23;335(2):417-23.
30	Sulfation of benzyl alcohol by the human cytosolic sulfotransferases (SULTs): a systematic analysis. J Appl Toxicol. 2016 Sep;36(9):1090-4.
31	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
32	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
33	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
34	Azimilide. Drugs. 2000 Feb;59(2):271-7; discussion 278-9.
35	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
36	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
37	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
38	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.